Previous clinical studies with the MarginProbe (MP) system demonstrated the MP System diagnostic accuracy for identification of cancerous/abnormal tissue at the margins (≤ 1mm) of the ex-vivo lumpectomy specimen. The current study is a prospective data collection study with the enhanced technology, the MP2.0 System and is aimed at collecting data to optimize the system algorithm/procedure and to subsequently validate the system to demonstrate non-inferiority to the MP1.x system.

In this study, MP2.0 system will be used on ex-vivo lumpectomy specimens at the Operating Room (OR). The study will collect a library of case information data using the MP2.0 system in sequential cohorts of a minimum of 50 subjects until the software and procedure are optimized. The final analysis sample size will be determined and outlined in the SAP based upon the results of the optimization stage.

Inclusion Criteria:

1. Women over 18 years of age
2. Diagnosed with cancer, undergoing lumpectomy or partial mastectomy procedure
3. Signed Informed Consent Form

Exclusion Criteria:

1. Undergoing re-excision procedure
2. Concurrent infectious disease
3. Pregnancy
4. Lactation
5. Previous surgery in the same site including open biopsy procedure, previous breast reduction or mastopexy in the operated breast
6. Prior radiation treatment in the operated breast
7. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study

The study will include measurements in cohorts of a minimum of 50 subjects up to a maximum of 1000 cases from women, aged 18 and above, undergoing breast lumpectomy/partial mastectomy surgery for previously diagnosed breast cancer.